Adma Biologics, Inc.ADMA
What Adma Biologics, Inc. does.
Unless the context otherwise requires, references in this Business section to “ADMA,” “ADMA Biologics,” the “Company,” “we,” “us” and “our” refer to ADMA Biologics, Inc., a Delaware corporation, as well as its wholly owned subsidiaries, ADMA BioManufacturing, LLC, a Delaware limited liability company (“ADMA BioManufacturing”), ADMA BioCenters Georgia Inc., a Delaware corporation (“ADMA BioCenters”) and ADMA Plasma Biologics, Inc., a Delaware corporation (“ADMA Plasma Biologics”).
We are a U.S. based end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Our targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons.
Through our ADMA BioManufacturing business segment, we currently have three products with U.S. Food and Drug Administration (the “FDA”) approval, all of which are currently marketed and commercially available: (i) ASCENIV (Immune Globulin Intravenous, Human – slra 10% Liquid), an Intravenous Immune Globulin (“IVIG”) product indicated for the treatment of Primary Humoral Immunodeficiency (“PI”), also known as Primary Immunodeficiency Disease (“PIDD”) or Inborn Errors of Immunity, in adults and adolescents, for which we received FDA approval in April 2019 and commenced first commercial sales in October 2019; (ii) BIVIGAM, an IVIG product indicated for the treatment of PI in adults and pediatric
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $42.2M | $80.9M | $154.1M | $258.2M | $426.5M | $510.2M |
| Net income | -$75.7M | -$71.6M | -$65.9M | -$28.2M | $197.7M | $146.9M |
| Free cash flow | -$114.7M | -$125.9M | -$73.4M | $4.0M | $110.4M | $27.8M |
More on ADMA.
- Adma Biologics, Inc. summary
- Adma Biologics, Inc. financial statements
- Adma Biologics, Inc. key metrics
- Adma Biologics, Inc. health scores and style box
- Adma Biologics, Inc. earnings
- Adma Biologics, Inc. dividends
- Adma Biologics, Inc. valuation
- Adma Biologics, Inc. ownership and insiders
- Adma Biologics, Inc. peers
Figures from Adma Biologics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.